IL11 and cancer: Our characterisation of the IL-11 signalling inhibitor, IL-11 Mutein, shows that it is highly effective at blocking signalling complex formation and potently inhibits signalling in a range of human cancer cell lines, highlighting the breadth of disease applications for emerging IL-11 signalling therapeutics.